omniture
logo
Search
科济生物医药（上海）有限公司
Media Room

Photo News

rss
CARsgen Announced 2023 Annual Results

CARsgen Announced 2023 Annual Results

2024-03-27 20:50 1871
CARsgen Announces Formation of its Clinical Advisory Board

CARsgen Announces Formation of its Clinical Advisory Board

2023-11-20 21:50 2369
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

2023-10-12 20:50 1396
CARsgen Announced 2023 Interim Results

CARsgen Announced 2023 Interim Results

2023-08-22 19:30 3123
CARsgen Announced 2022 Annual Results and Business Updates

CARsgen Announced 2022 Annual Results and Business Updates

2023-03-22 20:50 1993
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

2022-10-31 21:30 2522
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

2022-08-24 20:50 2614
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

2022-08-18 20:50 1687
CARsgen Appoints Dr. Hua Jiang as Executive Director

CARsgen Appoints Dr. Hua Jiang as Executive Director

2022-08-02 20:50 1934
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

2022-04-07 23:42 2224
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

2022-03-23 20:50 1493
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

2022-03-23 20:50 3014
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

2022-01-17 21:50 2129